Lipid encapsulation of cationic polymers in hybrid nanocarriers reduces their non-specific toxicity to breast epithelial cells

Pharmaceutical Research

Volumn 30, Issue 2, 2013, Pages 572-583

  Xue, Hui Yi ^a   Narvikar, Mayuri ^a   Zhao, Juan Bao ^a   Wong, Ho Lun ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

cationic polymer; hybrid nanocarrier; lipid; nonviral delivery; toxicity

Indexed keywords

CASPASE 3; LACTATE DEHYDROGENASE; LIPOFECTAMINE; NANOCARRIER; POLYMER; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA;

ARTICLE; BREAST EPITHELIUM; CANCER CELL CULTURE; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CYTOTOXICITY TEST; DOWN REGULATION; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LC 50; MEMBRANE DAMAGE; NANOENCAPSULATION; NANOTECHNOLOGY; PARTICLE SIZE; PRIORITY JOURNAL; VALIDATION PROCESS; ZETA POTENTIAL;

BREAST; CASPASE 3; CATIONS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; EPITHELIAL CELLS; FEMALE; HUMANS; LIPIDS; MITOCHONDRIA; NANOSTRUCTURES; POLYETHYLENEIMINE; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING;

EID: 84873422334     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0902-6     Document Type: Article

References (45)

1. Nimesh S, Gupta N, Chandra R. Cationic polymer based nanocarriers for delivery of therapeutic nucleic acids. J Biomed Nanotech. 2011;7(4):504-20.
2. Zhu L, Mahato RI. Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv. 2010;7(10):1209-26.
3. Donkuru M, Badea I, Wettig S, Verrall R, Elsabahy M, Foldvari M. Advancing nonviral gene delivery: lipid- and surfactant-based nanoparticle design strategies. Nanomedicine. 2010;5(7):1103-27.
4. Ewert KK, Zidovska A, Ahmad A, Bouxsein NF, Evans HM, McAllister CS, et al. Cationic liposome-nucleic acid complexes for gene delivery and silencing: pathways and mechanisms for plasmid DNA and siRNA. Topics Curr Chem. 2010;296:191-226.
5. Brower V. Cancer gene therapy steadily advances. J Natl Cancer Inst. 2008;100(18):1276-8.
6. Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, Tangney M. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther. 2008;8(2):66-78.
7. Sliva K, Schnierle BS. Selective gene silencing by viral delivery of short hairpin RNA. Virol J. 2010;7:248-59.
8. Guo J, Fisher KA, Darcy R, Cryan JF, O'Driscoll C. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol Biosyst. 2010;6(7):1143-61.
9. Elsabahy M, Nazarali A, Foldvari M. Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv. 2011;8(3):235-44.
10. Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev. 2007;59:164-82.
11. Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006;114:100-9.
12. Kumar VV, Singh RS, Chaudhuri A. Cationic transfection lipids in gene therapy: successes, set-backs, challenges and promises. Curr Med Chem. 2003;10:1297-306.
13. Demeneix B, Behr JP. Polyethylenimine (PEI). Adv Genet. 2005;53:217-30.
14. Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine)-mediated gene delivery affects endothelial cell function and viability. Biomaterials. 2001;22:471-80.
15. Breunig M, Lungwitz U, Liebl R, Goepferich A. Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci USA. 2007;104:14454-9.
16. Kluza E, Yeo SY, Schmid S, Van Der Schaft DW, Boekhoven RW, Schiffelers RM, et al. Anti-tumor activity of liposomal glucocorticoids: the relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. J Control Release. 2011;151(1):10-7.
17. Al-Ghananeem AM, Malkawi AH, Muammer YM, Balko JM, Black EP, Mourad W, et al. Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations. AAPS Pharm Sci Tech. 2009;10(2):410-7.
18. Ahn CH, Chae SY, Bae YH, Kim SW. Biodegradable poly(ethylenimine) for plasmid DNA delivery. J Control Release. 2002;80:273-82.
19. Dehshahri A, Oskuee RK, Shier WT, Hatefi A, Ramezani M. Gene transfer efficiency of high primary amine content, hydrophobic, alkyl-oligoamine derivatives of polyethylenimine. Biomaterials. 2009;30:4187-94.
20. Bonnet ME, Erbacher P, Bolcato-Bellemin AL. Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm Res. 2008;25:2972-82.
21. Masotti A, Moretti F, Mancini F, Russo G, Di Lauro N, Checchia P, et al. Physicochemical and biological study of selected hydrophobic polyethylenimine-based polycationic liposomes and their complexes with DNA. Bioorgan Med Chem. 2007;15:1504-15.
22. Yamazaki Y, Nango M, Matsuura M, Hasegawa Y, Hasegawa M, Oku N. Polycation liposomes, a novel nonviral gene transfer system, constructed from cetylated polyethylenimine. Gene Ther. 2000;7:1148-55.
23. Xue HY, Wong HL. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials. 2011;32:2662-72.
24. Xue HY, Wong HL. Solid lipid-PEI hybrid nanocarrier: an integrated approach to provide extended, targeted and safer siRNA therapy of prostate cancer in an all-in-one manner. ACS Nano. 2011;5(9):7034-47.
25. Wong HL, Rauth AM, Bendayan R, Wu XY. Combinational treatment with doxorubicin and GG918 (Elacridar) using polymer-lipid hybrid nanoparticles (PLN) and evaluation of strategies for multidrug-resistance reversal in human breast cancer cells. J Control Release. 2006;116:275-84.
26. Wong HL, Bendayan R, Rauth AM, Wu XY. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci. 2004;93:1993-2008.
27. Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008;2(8):1696-702.
28. Liu Y, Li K, Pan J, Liu B, Feng SS. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of docetaxel. Biomaterials. 2010;31(2):330-8.
29. Raemdonck K, Vandenbroucke RE, Demeester J, Sanders NN, De Smedt SC. Maintaining the silence: reflections on long-term RNAi. Drug Discov Today. 2008;13:917-31.
30. Salvador-Morales C, Zhang L, Langer R, Farokhzad OC. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials. 2009;30(12):2231-40.
31. West JD, Stamm CE, Kingsley PJ. Structure-activity comparison of the cytotoxic properties of diethyl maleate and related molecules: identification of diethyl acetylenedicarboxylate as a thiol cross-linking agent. Chem Res Toxicol. 2011;24(1):81-8.
32. Danielsen PH, Møller P, Jensen KA, Sharma AK, Wallin H, Bossi R, et al. Oxidative stress, DNA damage, and inflammation induced by ambient air and wood smoke particulate matter in human A549 and THP-1 cell lines. Chem Res Toxicol. 2011;24(2):168-84.
33. Amodio G, Moltedo O, Monteleone F, D'Ambrosio C, Scaloni A, Remondelli P, et al. Proteomic signatures in thapsigargin-treated hepatoma cells. Chem Res Toxicol. 2011;24(8):1215-22.
34. Bonnet ME, Erbacher P, Bolcato-Bellemin AL. Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm Res. 2008;25:2972-82.
35. Bertschinger M, Chaboche S, Jordan M, Wurm FM. A spectrophotometric assay for the quantification of polyethylenimine in DNA nanoparticles. Anal Biochem. 2004;334(1):196-8.
36. Cury-Boaventura MF, Gorjão R, de Lima TM, Newsholme P, Curi R. Comparative toxicity of oleic and linoleic acid on human lymphocytes. Life Sci. 2006;78(13):1448-56.
37. Cheng G, Zhu L, Mahato RI. Caspase-3 gene silencing for inhibiting apoptosis in insulinoma cells and human islets. Mol Pharm. 2008;5(6):1093-102.
38. Schäfer J, Höbel S, Bakowsky U, Aigner A. Liposome- polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials. 2010;26:6892-900.
39. Landen Jr CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, et al. Therapeutic Epha2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005;65(15):6910-8.
40. Li W, Szoka Jr FC. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res. 2007;24(3):438-49.
41. Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochem et Biophys Acta. 2009;1788(10):2259-66.
42. Wong HL, Rauth AM, Bendayan R, Wu XY. Evaluation of the in vivo efficacy, toxicity and lymphatic drainage of loco-regional administered polymer-lipid hybrid nanoparticles (PLN) loaded with doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm. 2007;65:300-8.
43. Muller RH, Ruhl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 1997;14:458-62.
44. Chen H, Ahn R, Van den Bossche J, Thompson DH, O'Halloran TV. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther. 2009;8(7):1955-63.
45. Wong HL, Xue HY. Evaluation of a megalin-targeting strategy to improve small-interfering RNA delivery to drug-resistant breast cancer. Era of Hope Conference (DOD Breast Cancer Research Program). 2011.